A presentation by new molybdenum-99 supplier SHINE Medical Technologies adds more support to Lantheus' (LNTH) position in the market being more secure than the current stock price reflects, Jefferies analyst Raj Denhoy tells investors in a research note. SHINE expects to bring production online in 2021, with Lantheus already contracted to use its molybdenum-99, the analyst adds. He believes the market is "vastly overestimating" the threat from new entrants and "vastly underappreciating" the company's "hold on this market." Denhoy sees little chance of BWX Technologies (BWXT) gaining significant traction given the manufacturing and regulatory challenges in bringing a generator to market. He keeps a Buy rating on Lantheus with a $21 price target.